Eun Kyung Joanne Lee, MD,MS
Psychiatry · Sacramento
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Has dropped Medicare — you would pay privately
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lee’s office at (650) 459-4078 to ask if they take your plan before you enroll.
California Medical Board record
Licence A145174 · Current
Licensed to practise in California · since 2016 · expires 2028-06-30 · David Geffen School of Medicine at UCLA.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$11,608
Pharmacies billed $11,608 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 295) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
295 generic and 0 brand-name prescriptions · $11,608 in drug cost · 43 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Aripiprazole | 11 | $5,127 | $466 |
| Clozapine | 24 | $619 | $26 |
| Buspirone | 17 | $572 | $34 |
| Gabapentin | 18 | $463 | $26 |
| Quetiapine | 12 | $444 | $37 |
See all 11 drugs
| Aripiprazole | 11 | $5,127 | $466 |
| Clozapine | 24 | $619 | $26 |
| Buspirone | 17 | $572 | $34 |
| Gabapentin | 18 | $463 | $26 |
| Quetiapine | 12 | $444 | $37 |
| Fluoxetine | 30 | $438 | $15 |
| Mirtazapine | 13 | $332 | $26 |
| Lamotrigine | 14 | $328 | $23 |
| Escitalopram | 25 | $318 | $13 |
| Sertraline | 13 | $198 | $15 |
| Clonazepam | 15 | $114 | $8 |
Year by year
| 2024 | 295 | 54 | 0% (0) | 0% | $11,608 |
| 2023 | 413 | 68 | 0% (0) | 4% | $18,050 |
| 2022 | 254 | 50 | 0% (0) | None | $14,745 |
| 2021 | 170 | 42 | 0% (0) | None | $6,450 |
| 2020 | 114 | 31 | 0% (0) | None | $13,506 |
| 2019 | 76 | 36 | 0% (0) | 0% | $2,207 |
| 2018 | 75 | 23 | 0% (0) | None | $10,978 |
| 2017 | 18 | None | 0% (0) | 0% | $411 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Quetiapine | 45 | $950 | $21 |
| Mirtazapine | 21 | $732 | $35 |
| Buspirone | 15 | $680 | $45 |
| Clozapine | 24 | $583 | $24 |
| Gabapentin | 24 | $569 | $24 |
| Venlafaxine Hcl Er | 13 | $504 | $39 |
| Escitalopram | 26 | $500 | $19 |
| Bupropion Xl | 19 | $441 | $23 |
| Lamotrigine | 16 | $387 | $24 |
| Fluoxetine | 28 | $364 | $13 |
| Dextroamphetamine-Amphetamine | 16 | $305 | $19 |
| Trazodone | 12 | $260 | $22 |
| Risperidone | 13 | $220 | $17 |
| Sertraline | 14 | $185 | $13 |
| Aripiprazole | 12 | $142 | $12 |
| Clonazepam | 17 | $109 | $6 |
| Alprazolam | 12 | $74 | $6 |
2022: 10 drugs
| Quetiapine | 19 | $1,655 | $87 |
| Olanzapine | 12 | $1,459 | $122 |
| Buspirone | 14 | $723 | $52 |
| Clozapine | 22 | $704 | $32 |
| Bupropion Xl | 22 | $456 | $21 |
| Escitalopram | 22 | $404 | $18 |
| Mirtazapine | 14 | $392 | $28 |
| Venlafaxine Hcl Er | 12 | $374 | $31 |
| Fluoxetine | 21 | $346 | $16 |
| Gabapentin | 13 | $270 | $21 |
2021: 5 drugs
| Dextroamphetamine-Amphetamine | 14 | $1,073 | $77 |
| Bupropion Xl | 14 | $692 | $49 |
| Clozapine | 11 | $690 | $63 |
| Escitalopram | 13 | $199 | $15 |
| Lorazepam | 15 | $109 | $7 |
Money from drug and device companies
$762 in 2025
A payment is not proof that care is biased.
| Axsome Therapeutics | Auvelity | $264 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $260 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $129 | 1 payment
|
| Teva Pharmaceuticals USA | Uzedy | $109 | 1 payment
|
See all 6 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-04 | Caplyta | $130 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-09 | Cobenfy | $129 |
| Teva Pharmaceuticals USA | Meals · 2025-08-19 | Uzedy | $109 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-03 | Caplyta | $130 |
| Axsome Therapeutics | Meals · 2025-05-06 | Auvelity | $125 |
| Axsome Therapeutics | Meals · 2025-03-25 | Auvelity | $138 |
Professional record
- NPI
- 1245626639
- Licence
- CA 145174California A145174: Current · expires 2028-06-30
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 1401 21st St Ste 11521, Sacramento, CA, 95811
- NPI first listed
- 2015-04-13
- NPI last updated
- 2026-07-20
- NPI record certified
- 2026-07-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 401 Quarry Rd, Palo Alto, CA, 94304